Dr. Valent is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
9500 Euclid Ave
Cleveland, OH 44195Phone+1 216-445-7238- Is this information wrong?
Summary
- Dr. Jason Valent is an oncologist in Cleveland, OH and is affiliated with Cleveland Clinic. He received his medical degree from University of Cincinnati College of Medicine and has been in practice 15 years. He specializes in hematologic oncology and is experienced in amyloidosis and multiple myeloma.
Education & Training
Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 2007 - 2010
University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 2002 - 2006
University of Cincinnati College of MedicineClass of 2002
Certifications & Licensure
OH State Medical License 2002 - 2025
MI State Medical License 2006 - 2013
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013
Clinical Trials
- The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Start of enrollment: 2016 Mar 01
Publications & Presentations
PubMed
- 2 citationsDaratumumab monotherapy for relapsed POEMS syndrome.Danai Dima, Jason Valent, Jack Khouri> ;American Journal of Hematology. 2023 Nov 1
- Clinical Efficacy of Retreatment With Venetoclax-Based Therapy in Relapsed-Refractory t(11;14) Multiple Myeloma.Danai Dima, Mark Orland, Fauzia Ullah, Faiz Anwer, Sandra Mazzoni, Shahzad Raza, Chakra P Chaulagain, Christy Samaras, Jason Valent, Louis Williams, Jack Khouri> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Nov 1
- 1 citationsManagement of Relapsed-Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice.Danai Dima, Fauzia Ullah, Sandra Mazzoni, Louis Williams, Beth Faiman, Austin Kurkowski, Chakra Chaulagain, Shahzad Raza, Christy Samaras, Jason Valent, Jack Khouri, F...> ;Cancers. 2023 Apr 5
- Join now to see all
Abstracts/Posters
- Depth of Pre-Treatment Immunoparesis Is an Important Prognostic Factor for Survival in Relapsed Multiple MyelomaJason Valent, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Rapid Infusion Daratumumab Is Safe in Patients with AL AmyloidosisJason Valent, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- External Validation of the Impede VTE Risk Score in Newly Diagnosed Multiple Myeloma (MM) PatientsJason Valent, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Preclinical Studies and a Phase I Trial of the TGF-β Receptor Inhibitor, Vactosertib (TEW-7197), in Combination with Pomalidomide in Patients with Multiple Myeloma Ref...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Rapid Hematologic and Organ Responses with Daratumumab, Bortezomib and Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Impact of Clinical Versus Biochemical Progression on Post-Progression Survival in Multiple Myeloma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Authored Content
- ASH 2020 Study Preview: Dose Escalation of Cael-101 in AL Amyloidosis PatientsDecember 2020
Press Mentions
Reader Responses: Should a Mostly Asymptomatic Patient with Amyloidosis Receive Systemic Therapy?May 1st, 2021- Fortress Biotech Announces Oral and Poster Data Presentations at the 62nd American Society of Hematology (ASH) Annual MeetingNovember 4th, 2020
Study Tests Targeted Drugs for Multiple MyelomaApril 1st, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
